Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma Group Limited has requested a trading halt on its securities pending the release of a material announcement regarding a proposed acquisition by Cosette through a scheme of arrangement. This move is expected to have significant implications for the company’s operations and market positioning, as it could potentially lead to strategic realignment and impact stakeholders involved.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX). The company is involved in the development and manufacturing of branded and generic pharmaceutical products, with a focus on delivering innovative solutions in the healthcare sector.
Average Trading Volume: 446,792
Technical Sentiment Signal: Sell
Current Market Cap: A$381.9M
See more insights into MYX stock on TipRanks’ Stock Analysis page.